Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LYL845 |
Synonyms | |
Therapy Description |
LYL845 are polyclonal autologous tumor infiltrating lymphocytes, which potentially result in increased cytokine release and enhanced antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LYL845 | LYL-845|LYL 845 | LYL845 are polyclonal autologous tumor infiltrating lymphocytes, which potentially result in increased cytokine release and enhanced antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05573035 | Phase I | LYL845 | A Study to Investigate LYL845 in Adults With Solid Tumors | Active, not recruiting | USA | 0 |